TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02631538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be provided as a 100 mg concentrated solution for infusion. It is a clear, colorless liquid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab will be provided as a 100 mg concentrated solution for infusion. It is a clear, colorless liquid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo belimumab
Description: The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo belimumab
Description: The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo belimumab
Description: The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo rituximab
Description: Placebo rituximab will be provided as solution for infusion. It is a clear, colorless liquid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo rituximab
Description: Placebo rituximab will be provided as solution for infusion. It is a clear, colorless liquid.
Study: NCT04396509

Intervention type: BEHAVIORAL
Intervention: Maternal Attachment Inventory Score
Description: three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken.

Intervention type: BEHAVIORAL
Intervention: Maternal Attachment Inventory Score
Description: three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken.
Study: NCT01964001

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B-6
Description: Vitamin B-6 50 mg/d

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: Coenzyme Q10 300 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B-6+Coenzyme Q10
Description: Vitamin B-6 (50 mg/d) and Coenzyme Q10 (300 mg/d)
Study: NCT02576184

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biologic Mesh
Description: Biologic mesh placed in retromuscular position during ileostoma closure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthetic Mesh
Description: synthetic mesh placed in retromuscular position during ileostoma closure
Study: NCT03032380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: 2000 mg intravenously every 8 hours for a period of 7 to14 days (dosage adjustment is necessary based on renal function)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: 2000 mg intravenously every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 600 mg of linezolid administered intravenously over 30 minutes to 2 hours, every 12 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: 600 mg of linezolid administered intravenously over 30 minutes to 2 hours, every 12 hours.
Study: NCT01258569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entereg
Description: Alvimopan (Entereg), an oral peripherally- acting mu-opioid receptor antagonist, is the first and only drug approved by the FDA to accelerate the time to upper and lower GI recovery in after partial large or small bowel resection surgery with primary anastomosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entereg
Description: oral, 12 mg 30-300 min pre-op then BID up to 7 days (or 15 total doses)
Study: NCT01964001

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: starch
Study: NCT02373111

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Isoflavone

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01406067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Program for Children with Aggressive Behavior
Description: 24 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 10 sessions with relatives of the child in most cases with the parents.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Play group
Description: 12 double sessions (totally 24 treatment hours) in groups with up to 5 children. Different play activities were presented including techniques to activate resources of the child. These interventions give the children the opportunity to train pro-social interactions. Additionally up to 3 parent sessions were also included.
Study: NCT02856750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 300 mg three times daily x30 days
Study: NCT01183273

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microlaparoscopic gastric bypass
Description: microlaparoscopic gastric bypass will be performed using standard of care procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Surgery
Description: laparoscopic gastric bypass will be performed using standard of care procedure.
Study: NCT01258569

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 12 mg oral 30-300 min pre-op then BID up to 7 days (or 15 doses)
Study: NCT01127789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation
Study: NCT02628080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone
Description: Atovaquone has an EU marketing authorisation (held by Glaxo Wellcome UK Ltd) and is indicated for acute treatment of mild to moderate Pneumocystis pneumonia (PCP). It is also used in combination with proguanil for malaria prophylaxis.
Study: NCT02686008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Patients will receive olaparib administered at 300 mg bid x 14 days orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Patients will receive olaparib administered at 300 mg bid x 14 days orally
Study: NCT03986593

Intervention type: DEVICE
Group type: OTHER
Intervention: cryoablation
Description: cryoablation of bone metastases by cone beam-CT image-guidance
Study: NCT04416360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview by psychologists
Description: Interviews for children / teenagers and parents :~* The questions encourage a narrative~* Repeated interviews: during confinement, at the end of confinement, and 3 months after the end of confinement~* Interviews carried out by videoconference, by trained psychologists not involved in the care process~Interview for referring caregivers: a single interview of approximately 45 minutes, 3 months post-confinement
Study: NCT01484886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Description: 10cc/kg weight RBC transfusion as needed according to hemoglobin level

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Description: 10cc/kg weight RBC transfusion as needed according to hemoglobin level

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Description: 10cc/kg body weight RBC will be transfused for hemoglobin under 9.5 for biventricular repairs and under 12 for single ventricle palliations.
Study: NCT01757717

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ir-192 high dose rate (HDR)
Description: Patients will be followed at 2 months (+/- 2 weeks) post-treatment and then approximately every 3 months (+/- 2 weeks) until approximately 11 months of follow up. They will be evaluated for pain referable to the treated site, clinical and radiographic evidence of local progression, and treatment related toxicity. Thereafter, patients will be followed as clinically indicated.
Study: NCT04353778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridostigmine
Description: Eight weeks of low-dose pyridostigmine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: matching placebo x 8 weeks
Study: NCT03426020

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral midazolam
Description: 0.5 mg/kg oral midazolam administered 20 minutes before induction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor
Description: patients will be watched a short movie (at URL: http://www.animaturk.com/animasyon/suko-ameliyat-oluyor ) 20 minutes before induction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Play game (PC fishing game)
Description: Patients will be played a simple PC game (a fishing game) 20 minutes before induction
Study: NCT03321448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMTP1-ICG
Description: Detection of SLN

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICG
Description: Detection of SLN
Study: NCT00841737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational group
Description: The intervention group receive weekly a psychoeducational group during 12 weeks run by 2 nurses. The program have a structures contend.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: In the control group the depression is treated as usual with the conventional treatment.
Study: NCT03922854

Intervention type: OTHER
Intervention: Non-interventional data collection only
Description: There is no clinical intervention. This study is just capturing data from devices used part of routine clinical care. The results of this data collection will be analysed to inform study results.
Study: NCT03569852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restrictive Feeding
Description: Volunteers will adhere to a form of time restrictive feeding, 16 hours fasting and 8 hours eating per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restrictive Feeding
Description: Volunteers will adhere to a form of time restrictive feeding, 16 hours fasting and 8 hours eating per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Eating Pattern
Description: Volunteers will adhere to a more traditional eating pattern, 12 hours fasted and 12 hours eating per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Eating Pattern
Description: Volunteers will adhere to a more traditional eating pattern, 12 hours fasted and 12 hours eating per day.
Study: NCT01482910

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Participants in the VEGF Trap-Eye group received intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks for an overall treatment period of 48 weeks. Additionally, sham PDT treatments was administered as needed.
Study: NCT04353778

Intervention type: PROCEDURE
Group type: OTHER
Intervention: non-invasive vagal nerve stimulation
Description: stimulation of the vagus nerve
Study: NCT01482910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visudyne
Description: Participants in the PDT group (Visudyne group) received Visudyne as needed. Additionally, sham IVT injections was administered until week 28. Thereafter, subjects in the PDT group received active (= no sham) VEGF Trap-Eye treatment until week 48.
Study: NCT02656628

Intervention type: DEVICE
Intervention: Dynamic Locking Screw 3.7mm and 5.0mm
Description: Treatment with DLS and locked plate constructs (small or large fragments)
Study: NCT03803969

Intervention type: DEVICE
Group type: OTHER
Intervention: ConfirmRx (Insertable Cardiac Monitor)
Description: This study is designed to characterise the safety and performance of the ConfirmRx device by assessing quality of signal attained from the device with changes in posture and physical activity at implant and 30days post procedure. The study is also intended to assess gross migrations of the device at 30days post implant.
Study: NCT03818035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive 100 mg guselkumab subcutaneously at Weeks 0, 4, 12 and 20 (group 1), at weeks 28, 36, 44, 52, 60 (group 2a and 2c), and at weeks 36 and 52 (group 2b). Group 2d and 3c are the re-treatment groups and will receive three injections after loss of disease control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive 100 mg guselkumab subcutaneously at Weeks 0, 4, 12 and 20 (group 1), at weeks 28, 36, 44, 52, 60 (group 2a and 2c), and at weeks 36 and 52 (group 2b). Group 2d and 3c are the re-treatment groups and will receive three injections after loss of disease control.
Study: NCT04464213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single dose experiments
Description: In single dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient only receive treatment once time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-dose experiments
Description: In multi-dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient receive treatment on six consecutive days.
Study: NCT03658369

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lanconone®
Description: 2 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Methyl crystalline cellulose
Description: 2 Capsules
Study: NCT04210466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance & Commitment Therapy + Compassion (COMP.ACT)
Description: 8 sessions, 2h each. Intervention includes meditation exercises, behavioral exercises, group discussions, and the structure is the following Session 1: INTRODUCTION: control is the problem Session 2: THE BODY AS PRESENT: promoting body awareness through mindfulness Session 3: COMPASSION I: from self-criticism to self-care Session 4: COMPASSION II: the body as an anchor to self-compassion Session 5: ACCEPTANCE: there is more to accept than just pain Session 6: (RE)DISCOVERING VALUES: in search of a valued life Session 7: ACT NOW: from values to committed action Session 8: CARRY ON AFTER COMP.ACT: program summary

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy (ACT)
Description: 8 sessions, 2h each. Intervention includes meditation exercises, behavioral exercises, group discussions, and the structure is the following Session 1: INTRODUCTION: control is the problem Session 2: THE BODY AS PRESENT: promoting body awareness through mindfulness Session 3: Q\&A 1 Session 4: Q\&A 2 Session 5: ACCEPTANCE: there is more to accept than just pain Session 6: (RE)DISCOVERING VALUES: in search of a valued life Session 7: ACT NOW: from values to committed action Session 8: CARRY ON AFTER COMP.ACT: program summary
Study: NCT00173862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Ifosfamide
Study: NCT03558347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: short implants with splinted crowns
Description: 7 mm short implants (CONELOG® Implant System), individualized titanium abutments, splinted lithium disilicate crowns

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: short implants with non-splinted crowns
Description: 7 mm short implants (CONELOG® Implant System), individualized titanium abutments, non-splinted lithium disilicate crowns
Study: NCT01846286

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Five questionnaires about pain and symptoms, each taking approximately 25 - 50 minutes to complete

Intervention type: OTHER
Intervention: Quantitative Sensory Testing
Description: Tests measure sensitivity to touch, coolness, warmth, hot/cold feeling, and pin pricks. The sensory tests will take about 30 minutes to 1 hour to complete.
Study: NCT02900703

Intervention type: BIOLOGICAL
Intervention: stool samples
Study: NCT00882141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet modification
Description: Weight loss sessions are held by a registered dietitian for 1 hour once a week for 6-9 months; recommended caloric intake to elicit a weight loss of approximately 0.2-0.4 kg per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet modification
Description: Weight loss sessions are held by a registered dietitian for 1 hour once a week for 6-9 months; recommended caloric intake to elicit a weight loss of approximately 0.2-0.4 kg per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Treadmills and other aerobic exercise equipment 3 times a week for 6-9 months, beginning at low levels of VO2max and progressing in duration and intensity to more than 75% VO2max for 45 minutes
Study: NCT02945956

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir
Description: The subjects will be taking 1 Entecavir tablet per day for 96 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir + Fuzheng Huayu
Description: The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
Study: NCT01046695

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS Unit
Description: TENS is a method of pain relief that uses a battery operated electronic device with cutaneously applied electrodes that deliver electrical signals to peripheral nerves through the intact skin. The TENS Unit is a low voltage system that will only be used to a level to create alternative to pain sensation and will not create muscle response.
Study: NCT00510185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: systematic coronary intervention
Description: Coronary angiography within 72 hrs

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: coronary intervention only for cases refractory to medical therapy
Description: Initially conservative treatment with coronary angiography only for recurrent ischemia
Study: NCT04282031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-1178
Description: BPI-1178 once daily on Days 1 to 21 of a 28-day cycle
Study: NCT04483401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Occupational Performance (CO-OP)
Description: Intervention: CO-OP is a cognitive approach to solving functional motor problems (Polatajko et al., 2001b). Therapists teach children a global problem solving strategy (Goal-Plan-Do-Check) as a framework for developing specific strategies for overcoming motor problems; these strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. CO-OP intervention will be administered by occupational therapists who have been trained in the CO-OP approach. Children will be seen once weekly for one hour over 12 weeks at as per published protocol (Polatajko et al., 2001b). Parents or caregivers will be encouraged to attend treatment sessions so that therapists can instruct them how to facilitate strategy use between treatment sessions. Children will select three functional motor goals to be addressed over the course of treatment, rating their performance and satisfaction of these goals pre- and post-intervention.
Study: NCT04958460

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administrated 1 packet of maltodextrin (as placebo of Bf-688) in the morning and evening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BF688
Description: Administrated 1 pack each morning and evening (5×109 CFUs per day)
Study: NCT04571671

Intervention type: OTHER
Intervention: Collect retrospectively data
Description: Analyse the incidence of Mullerian anomalies in these populations

Intervention type: OTHER
Intervention: Collect retrospectively data
Description: Analyse the incidence of Mullerian anomalies in these populations
Study: NCT02855918

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample for genetic purpose
Description: All the participants will performed the same evaluations and blood analysis :~* A clinical assessment by psychiatrist~* Self report questionnaires for the assessment of a potential mood disorder and history of SB, moral/physical pain, personality traits...~* A neuropsychological assessment for the evaluations of cognitive performances~* A routine blood sampling to the realization of a standard blood test~* A specific blood sampling (PAXgene® tubes) to extract total RNA of blood cells and measure the expression of ADARS RNA and editing of the PDE8A transcript.
Study: NCT03818035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Injection
Description: Participants of group 2b will receive matching placebo injection subcutaneously at weeks 28, 44 and 60.
Study: NCT01358877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administered as per the schedule specified in the respective arm.